Working… Menu

Ketoprofen 10% Cream for Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00765700
Recruitment Status : Completed
First Posted : October 3, 2008
Last Update Posted : September 27, 2013
Cato Research
Information provided by (Responsible Party):
Imprimis Pharmaceuticals, Inc.

Brief Summary:
Imprimis Pharmaceuticals is investigating a proprietary, topical cream formulation consisting of 10% ketoprofen (containing 100 mg of ketoprofen in 1gram of cream) for the local treatment of acute musculoskeletal pain.

Condition or disease Intervention/treatment Phase
Sprain Strain Acute Soft Tissue Injury Drug: Topical Ketoprofen 10% Cream Drug: Topical Placebo Cream Phase 3

Detailed Description:
The primary objective of this study is to determine the efficacy and safety of ketoprofen 10% cream compared to placebo as a three-times-per-day topical application in improving the patient assessment of pain when used to treat mild to moderate acute soft tissue injury of the upper and lower extremities over a 7-day period.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 364 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Assess the Efficacy and Safety of Ketotransdel™ (Ketoprofen Topical Cream 10%) in the Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury.
Study Start Date : September 2008
Actual Primary Completion Date : August 2009
Actual Study Completion Date : September 2009

Resource links provided by the National Library of Medicine

Drug Information available for: Ketoprofen

Arm Intervention/treatment
Active Comparator: Ketoprofen 10% Cream

Topical Ketoprofen 10% Cream

1gram three times daily for 7 days

Drug: Topical Ketoprofen 10% Cream
Topical Administration
Other Name: Ketotransdel (TDLP-110)

Placebo Comparator: Placebo

Topical placebo cream

1gram three times daily for 7 days

Drug: Topical Placebo Cream
Topical Administration
Other Names:
  • Placebo
  • Vehicle

Primary Outcome Measures :
  1. Assess the efficacy of ketoprofen 10% cream in subjects with acute pain associated with mild to moderate acute soft tissue injury (acute sprain or strain) of upper and lower extremities on the day 3 visit. [ Time Frame: 7 days ]

Secondary Outcome Measures :
  1. Assess the safety, tolerability and other parameters of ketoprofen 10% cream in subjects with acute pain associated with mild to moderate acute soft tissue injury of upper and lower extremities. [ Time Frame: 14 days ]

Other Outcome Measures:
  1. To assess the pharmacokinetics of ketoprofen after 7 days of topical application [ Time Frame: 8 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 to 70 years of age
  • Have a diagnosis of uncomplicated acute soft tissue injury of the upper or lower extremity that has occurred within the 72 hours preceding the baseline visit.
  • The injury site must be accessible to the patient so that he or she can apply the study treatment himself or herself.
  • Meet pain entry criteria.
  • Willing to discontinue use of any pain medication or treatments not provided as part of the study.

Exclusion Criteria:

  • Grade 3 sprain or strain, bilateral sprain or strain, or concomitant fracture or open wound at the site of the sprain or strain, or have a serious injury, as determined by the investigator (e.g., nerve damage, joint instability, or tendon rupture).
  • Previous injury to the same area within 3 months prior to current injury.
  • Active skin lesions or disease at the intended site of application of the study medication. Skin lesions include open wounds, rash, papules, vesicles, and erythema associated with the site of injury.
  • Pharmacologic treatment (NSAIDs or analgesic medications) for the injury less than 12 hours before the baseline assessments.
  • Any form of opioid use since the time of injury.
  • Any form of steroid use within 30 days prior to study entry.
  • Non-pharmacologic treatments of the injury other than rest, ice, compression, and/or elevation (RICE) prior to the baseline visit.
  • History or physical examination finding that is not compatible with safe participation in the study as determined by the study doctor, such as gastrointestinal (stomach, intestine) ulcer or bleeding within 6 months documented by an upper-gastrointestinal series (UGI x-ray, barium meal) or endoscopy (GI scope), anemia or abnormal bleeding, moderate to severe kidney disease, or moderate to severe liver disease.
  • A history of, or evidence for, underlying disease in the injured area, such as osteoarthritis or gout.
  • Clinically significant, poorly controlled lung, stomach, liver, kidney, heart, or other vital organ disease as determined by the study doctor or nurse.
  • A history of allergy to ketoprofen or ketoprofen-containing products.
  • A history of allergy to soy lecithin or soy lecithin-containing products.
  • Medications (drugs) or other substances contraindicated due to the nature of study medication that include:

    • Allergies to prescription or over-the-counter products containing acetaminophen (e.g., Tylenol®), which is used as rescue medication
    • History of aspirin-sensitive asthma, or aspirin-associated rhinitis or nasal polyps
    • Taking warfarin, parenteral heparin, ticlopidine or clopidogrel
    • Taking lithium or methotrexate
    • Taking probenecid or similar drugs that might affect the kidneys
  • Received an investigational drug or product or participated in an investigational drug study within a period of 30 days prior to receiving study medication.
  • Scheduled elective surgery or other invasive procedures during the period of study participation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00765700

Layout table for location information
United States, North Carolina
CATO Research
Durham, North Carolina, United States, 27713
Sponsors and Collaborators
Imprimis Pharmaceuticals, Inc.
Cato Research
Layout table for investigator information
Study Director: Illana Katsnelson, MD Cato Research
Publications of Results:
E. Ekman, S. Skrepnik, M. Jones , K. Lawson, and J. Schupp. EFFICACY AND SAFETY OF KETOPROFEN 10% CREAM IN ACUTE SOFT TISSUE INJURIES (PHASE 3 STUDY TDLP-110-001). Poster Presentation, Sep. 2, 2010, 13th World Congress on Pain in Montreal, Canada.

Layout table for additonal information
Responsible Party: Imprimis Pharmaceuticals, Inc. Identifier: NCT00765700    
Other Study ID Numbers: TDLP-110-101
First Posted: October 3, 2008    Key Record Dates
Last Update Posted: September 27, 2013
Last Verified: September 2013
Keywords provided by Imprimis Pharmaceuticals, Inc.:
Ankle Pain
Shoulder Pain
Elbow Pain
Tennis Elbow
Knee pain
Wrist Pain
Hand Pain
Muscle, Bone and Cartilage Disorders
Additional relevant MeSH terms:
Layout table for MeSH terms
Wounds and Injuries
Soft Tissue Injuries
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action